Publications by authors named "Ruth Werth"

Claim this Profile
1
17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
Sandrine Marchais-Oberwinkler, Claudia Henn, Gabriele Möller, Tobias Klein, Matthias Negri, Ruth Werth

J Steroid Biochem Mol Biol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17 β-hydroxysteroid dehydrogenase Type 1 (17 β-HSD1): the role of the bicyclic moiety.
Alexander Oster, Tobias Klein, Claudia Henn, Ruth Werth, Sandrine Marchais-Oberwinkler

ChemMedChem· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases.
Sandrine Marchais-Oberwinkler, Marie Wetzel, Erika Ziegler, Patricia Kruchten, Ruth Werth

J Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases.
Alexander Oster, Stefan Hinsberger, Ruth Werth, Sandrine Marchais-Oberwinkler, Martin Frotscher

J Med Chem· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
Alexander Oster, Tobias Klein, Ruth Werth, Patricia Kruchten, Emmanuel Bey

Bioorg Med Chem· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
Emmanuel Bey, Sandrine Marchais-Oberwinkler, Matthias Negri, Patricia Kruchten, Alexander Oster, Ruth Werth

J Med Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells.
Patricia Kruchten, Ruth Werth, Emmanuel Bey, Alexander Oster, Sandrine Marchais-Oberwinkler

J Steroid Biochem Mol Biol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2.
Yaseen A Al-Soud, Emmanuel Bey, Alexander Oster, Sandrine Marchais-Oberwinkler, Ruth Werth

Mol Cell Endocrinol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Sandrine Marchais-Oberwinkler, Martin Frotscher, Erika Ziegler, Ruth Werth, Patricia Kruchten

Mol Cell Endocrinol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
Patricia Kruchten, Ruth Werth, Sandrine Marchais-Oberwinkler, Martin Frotscher, Rolf W Hartmann

Mol Cell Endocrinol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
Emmanuel Bey, Sandrine Marchais-Oberwinkler, Ruth Werth, Matthias Negri, Yaseen A Al-Soud

J Med Chem· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Emmanuel Bey, Sandrine Marchais-Oberwinkler, Patricia Kruchten, Martin Frotscher, Ruth Werth

Bioorg Med Chem· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis